J. Graham's Profile

Role	Title	Level	Year	L/R
🐜	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial 48 auth. Nicholas D. James, Nicholas D. James, M. Sydes, N. Clarke, M. Mason, D. Dearnaley, M. Spears, A. Ritchie, C. Parker, J. Russell, G. Attard, J. Bono, W. Cross, Robert Jones, G. Thalmann, ... C. Amos, D. Matheson, R. Millman, M. Alzouebi, S. Beesley, A. Birtle, S. Brock, R. Cathomas, P. Chakraborti, S. Chowdhury, A. Cook, T. Elliott, J. Gale, S. Gibbs, J. Graham, J. Hetherington, R. Hughes, R. Laing, F. McKinna, D. McLaren, J. O’Sullivan, O. Parikh, C. Peedell, A. Protheroe, A. Robinson, N. Srihari, R. Srinivasan, J. Staffurth, S. Sundar, S. Tolan, D. Tsang, J. Wagstaff, M. Parmar	10	2016	10 🐜
🐜	Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial 29 auth. D. Dearnaley, I. Syndikus, H. Mossop, V. Khoo, A. Birtle, D. Bloomfield, J. Graham, P. Kirkbride, J. Logue, Z. Malik, J. Money-Kyrle, J. O’Sullivan, M. Panades, C. Parker, H. Patterson, ... C. Scrase, J. Staffurth, A. Stockdale, Jean Tremlett, M. Bidmead, H. Mayles, O. Naismith, C. South, A. Gao, C. Cruickshank, S. Hassan, J. Pugh, C. Griffin, E. Hall	9	2016	9 🐜
🐜	Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. 17 auth. D. Dearnaley, M. Sydes, J. Graham, E. Aird, D. Bottomley, R. Cowan, R. Huddart, Chakiath C Jose, J. Matthews, J. Millar, ... A. Moore, Rachel C. Morgan, J. Russell, C. Scrase, R. Stephens, I. Syndikus, M. Parmar	9	2007	9 🐜
🐜	Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. 30 auth. C. Sternberg, I. Skoneczna, J. Kerst, P. Albers, S. Fosså, M. Agerbæk, H. Dumez, M. D. Santis, C. Théodore, M. Leahy, J. Chester, A. Verbaeys, G. Daugaard, L. Wood, J. Witjes, ... R. D. Wit, L. Geoffrois, L. Sengeløv, G. Thalmann, D. Charpentier, F. Rolland, L. Mignot, S. Sundar, P. Symonds, J. Graham, F. Joly, S. Marréaud, L. Collette, R. Sylvester, Groupe d’Etude des Tumeurs Urogénitales	8	2015	8 🐜
🐜	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol 154 auth. G. Attard, L. Murphy, N. Clarke, W. Cross, Robert J. Jones, C. Parker, S. Gillessen, A. Cook, C. Brawley, C. Amos, N. Atako, C. Pugh, Michelle M. C. Buckner, S. Chowdhury, Z. Malik, ... J. Russell, C. Gilson, H. Rush, J. Bowen, A. Lydon, I. Pedley, J. O’Sullivan, A. Birtle, J. Gale, N. Srihari, Carys W Thomas, J. Tanguay, J. Wagstaff, P. Das, Emma Gray, Mymoona Alzoueb, O. Parikh, A. Robinson, I. Syndikus, J. Wylie, A. Zarkar, G. Thalmann, J. Bono, D. Dearnaley, M. Mason, D. Gilbert, R. Langley, R. Millman, D. Matheson, M. Sydes, L. Brown, M. Parmar, Nicholas D. James, E. Jones, K. Hyde, H. Glen, S. Needleman, U. McGovern, D. Sheehan, S. Paisey, R. Shaffer, M. Beresford, E. Porfiri, D. Fackrell, Ling-hui Lee, T. Sreenivasan, S. Brock, Simon Brown, A. Bahl, Mike Smith-Howell, C. Woodward, M. Phan, D. Mazhar, K. Narahari, F. Douglas, Ajay Kumar, A. Hamid, A. Ibrahim, D. Muthukumar, M. Simms, J. Worlding, A. Tran, M. Kagzi, C. Pezaro, Virgil Sivoglo, B. Masters, Pek Keng-Koh, C. Manetta, D. McLaren, Nishi Gupta, S. Boussios, H. Taylor, J. Graham, C. Perna, L. Melcher, Warren C. Grant, A. Sabharwal, U. Hofmann, R. Dealey, N. McPhail, R. Brierly, L. Capaldi, N. Sidek, P. Whelan, P. Robson, A. Falconer, S. Rudman, S. Vivekanandan, Vinod Mullessey, M. Vilarino-Varela, V. Khoo, K. Tipples, M. Afshar, P. Brulinski, V. Sangar, C. Peedell, A. Azzabi, P. Hoskin, Viwod Mullassery, S. Sundar, Yakhub Khan, R. Conroy, A. Protheroe, J. Carser, P. Rogers, K. Tarver, S. Gibbs, M. M. Khan, M. Hingorani, S. Crabb, M. Alameddine, N. Bhalla, R. Hughes, J. Logue, D. Leaning, Salil Vengalil, D. Ford, G. Walker, A. Shaheen, Omar Khan, Andrew Chan, I. Ahmed, S. Hilman, I. Sayers, A. Nikapota, D. Bloomfield, T. Porter, J. Joseph, C. Rentsch, R. P. Mestre, E. Roggero, Jörg Beyer, M. Borner, R. Strebel, D. Berthold, D. Engeler, Hubert John, Razvan Popescu, Donat Durr	7	2021	7 🐜
🐜	Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA) 92 auth. L. Franzén, S. Gibbs, J. Graham, A. Haese*, C. Hampel, R. Harrup, C. Heath, D. Heinrich, S. Helle, M. Hora, Peter Hoskin, G. Hudes, M. Jackson, Nick James, B. Jarzab, ... P. Jarzemski, Dag Clement Johannessen, W. Koff, U. Kasti, C. Keil, J. Kindblom, O. Klepp, R. Klijer, J. Kliment, L. Klotz, I. Kocák, Andrzej Kołodziejczyk, M. Kuczyk, P. Kwong, M. Lagerlund, K. Larsen, A. Leung, E. Leung, R. Llarena, M. Aglietta, D. Amadori, E. Aranda, J. Arbizu, A. Bahl, V. Baláž, P. Bello, R. Ben‐Yosef, I. Billiet, D. Bottomley, J. Breza, Michael Brown, W. Cabral, Micheal Cano, J. Carles, P. Chakraborti, P. Chłosta, A. Chodacki, R. Coleman, Marian Cvik, D. Dalley, M. Dall'oglio, R. Damião, M. D. Goeij, G. Dickie, S. Dixit, J. G. Donas, A. Dowling, Y. Dror, L. Duck, Monstserrat Estorch, U. Falkmer, D. Feltl, S. Fosså, J. Logue, Rafael López, Jarad M. Martin, G. Marx, B. Mellado, W. Mermershtain, C. Messina, J. Michalski, A. Miller, I. Mincik, J. Money-Kyrle, A. Monnier, André G Moraes, A. Murad, C. Ng, C. Nieder, Sten Nilsson, J. O’Sullivan, Christopher C. Parker, S. Pascoe, Samir Patel, A. Pecking, Jaroslav Pernicka, K. Pittman	7	2011	7 🐜
🐬	Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. A. Simpson, J. Paul, J. Graham, S. Kaye	7	1998	7 🐬
🐜	Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial 23 auth. A. Wilkins, H. Mossop, I. Syndikus, V. Khoo, D. Bloomfield, C. Parker, J. Logue, C. Scrase, H. Patterson, A. Birtle, ... J. Staffurth, Z. Malik, M. Panades, C. Eswar, J. Graham, M. Russell, P. Kirkbride, J. O’Sullivan, A. Gao, C. Cruickshank, C. Griffin, D. Dearnaley, E. Hall	7	2015	7 🐜
🐢	Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. 13 auth. J. D. de Bono, J. Bellmunt, G. Attard, J. Droz, K. Miller, A. Fléchon, C. Sternberg, C. Parker, G. Zugmaier, V. Hersberger-Gimenez, ... L. Cockey, M. Mason, J. Graham	7	2007	7 🐢
🐜	National implementation of multi‐parametric magnetic resonance imaging for prostate cancer detection – recommendations from a UK consensus meeting 26 auth. Mrishta Brizmohun Appayya, J. Adshead, H. Ahmed, C. Allen, A. Bainbridge, T. Barrett, F. Giganti, J. Graham, P. Haslam, E. Johnston, C. Kastner, A. Kirkham, Alexandra Lipton, A. McNeill, Larissa S. Moniz, ... C. Moore, G. Nabi, A. Padhani, C. Parker, Amit R. Patel, J. Pursey, J. Richenberg, J. Staffurth, J. H. van der Meulen, Darren Walls, S. Punwani	6	2018	6 🐜
🐜	Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. 12 auth. C. Sternberg, H. Dumez, H. Poppel, I. Skoneczna, A. Sella, G. Daugaard, ... T. Gil, J. Graham, P. Carpentier, F. Calabrò, L. Collette, D. Lacombe	6	2009	6 🐜
🐜	Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). 93 auth. Ann-Sofie Fransson, L. Franzén, S. Gibbs, J. Graham, A. Haese*, C. Hampel, R. Harrup, C. Heath, D. Heinrich, S. Helle, M. Hora, P. Hoskin, G. Hudes, M. Jackson, Nick D James, ... B. Jarzab, P. Jarzemski, D. Johannessen, W. Koff, U. Kasti, C. Keil, J. Kindblom, O. Klepp, R. Klijer, J. Kliment, L. Klotz, I. Kocák, Andrzej Kołodziejczyk, M. Kuczyk, P. Kwong, M. Lagerlund, K. Larsen, A. Leung, Eugene Leung, R. Llarena, M. Aglietta, D. Amadori, E. Aranda, J. Arbizu, A. Bahl, V. Baláž, P. Bello, R. Ben‐Yosef, I. Billiet, D. Bottomley, J. Breza, Michael Brown, W. Cabral, Micheal Cano, J. Carles, P. Chakraborti, P. Chłosta, A. Chodacki, Robb Coleman, Marian Cvik, D. Dalley, M. Dall'oglio, R. Damião, M. D. Goeij, G. Dickie, S. Dixit, J. G. Donas, A. Dowling, Y. Dror, L. Duck, Monstserrat Estorch, U. Falkmer, D. Feltl, S. Fosså, J. Logue, Rafael López, Jarad Martin, G. Marx, B. Mellado, W. Mermershtain, C. Messina, J. Michalski, A. Miller, I. Mincik, J. Money-Kyrle, A. Monnier, André G Moraes, A. Murad, C. Ng, C. Nieder, S. Nilsson, J. O’Sullivan, C. Parker, S. Pascoe, Samir C Patel, A. Pecking, Jaroslav Pernicka, K. Pittman	6	2012	6 🐜